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Abstract
Background: The aim of our study is to analyze survival, treatment-related morbidity, and safety in our experience
of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Methods: Sixty-four patients were treated. Survival curves were calculated according to the Kaplan-Meier method.
Univariate and multivariate analyses were done, and Cox’s proportional hazard model was used to identify
significant factors.
Results: Global 5-year overall survival was 55 %. Overall survival was also evaluated according to neutrophils
to lymphocytes ratio and neutrophils to platelets ratio. Overall survival according to pre-operative serum
albumin level shows a difference in the two groups (P < 0.05). We observed minor or no adverse events in
53 cases (89.8 %), while 3 patients (5.1 %) showed a grade III–IV complication and 3 post-operative deaths
(5.1 %). Post-operative complication also influenced overall survival; patients in whom a minor complication
occurred had a 3-year overall survival (OS) of 62 % vs. a 3-year OS of 28 % in patients who underwent a
major complication (P < 0.1).
Conclusions: Hyperthermic intraperitoneal chemotherapy (HIPEC) could be a valid and feasible option for
selected patients affected by gastrointestinal malignancies’ peritoneal carcinomatosis.
Pre-operative parameters could be evaluated to choose patient who could benefit from cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy.
Keywords: Peritoneal carcinomatosis, Gastrointestinal malignances, Intraperitoneal chemotherapy
Background
Peritoneal carcinomatosis (PC) has been considered as
a rapidly lethal disease and therefore mainly managed
by palliative options and conservative care.
Gastroenteric and ovarian cancers behave as the main
actors in the development of PC, which leads the pa-
tients to a very poor prognosis [1–3].
The treatment of PC is an expanding area in which a
multimodality therapy approach has been shown to sig-
nificantly increase overall survival.
Recently, the clinical interest on this clinical condi-
tion has increased for the encouraging results reported
combining cytoreductive surgery (CRS) and hyperther-
mic intraperitoneal chemotherapy (HIPEC) [4–6].
Surgical cytoreduction aims to remove all the periton-
eal visible disease, whereas HIPEC treatment attempts to
eliminate the occult carcinomatosis for the presence of
free cancer cells in the peritoneal cavity.
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This complex approach could include an extensive
peritonectomy, multiple organs resection, intraperito-
neal chemotherapy, and hyperthermia. Not surprisingly,
many trials reported a high morbidity comparable to
that of major surgery (Whipple procedure, gastrectomy
with an extensive lymphadenectomy) [7–9].
It has become crucial to understand whether we can
consider prognostic factors than can predict patients’
outcomes and post-surgical complications.
Although it is recognized that the development of can-
cer has a genetic basis, there is increasing evidence that
the host inflammatory response plays an important role
in the development and progression of cancer. Inflam-
matory biomarkers, such as neutrophil to lymphocyte
ratio (N/L), neutrophil to platelet ratio (N/P), and serum
albumin level, hold great promise for improving the pre-
dictive ability of existing prognostic tools in cancer pa-
tients [10]. N/L ratio seems to be related to the
prognosis of various types of cancer. In particular, a high
N/L ratio has been suggested to be associated with poor
outcome [11].
Moreover, in advanced tumors, a high pre-operative
C-reactive protein (CRP) level and/or high platelet count
were frequently observed and were associated with poor
patient prognosis [12].
The aim of our study is to analyze overall survival
(OS), treatment-related morbidity, and safety in our ini-
tial experience considering various prognostic factors
and their survival impact in patients undergoing CRS
and HIPEC.
Methods
Sixty-four consecutive patients with PC from different
primitive tumors have been treated in our center from
September 2006 to September 2014. A prospective col-
lected database has been created and data were retro-
spectively analyzed.
Eligibility requirements included the following: diagno-
sis of peritoneal surface malignancies (PSM) made or
confirmed in our Pathology Department, age 75 years or
younger, performance status 2 or less according to East-
ern Cooperative Oncology Group (ECOG), no significant
comorbidities, no extra-abdominal or hepatic metastases
in number superior to 3, and pre-operative computer
tomographic (CT) scan showing peritoneal disease
amenable to potentially complete surgical cytoreduction.
Average age was 59.6 ± 10.8 years old.
Median follow-up was 26.5 months (range 4–
120 months).
At the beginning of the surgical procedure, the abdo-
men was explored and Peritoneal Cancer Index (PCI)
was calculated by dividing the abdomen region into 13
quadrants and assigning a lesion size score according to
Sugarbacker carcinomatosis index [13]. Patients that
underwent adjuvant HIPEC treatment (gastric cancer
patients at high risk to develop PC with serosal involve-
ment or positive peritoneal cytology) were considered
with a PCI equal to zero.
Median PCI was 2 (range 0–19).
Patients were stratified into three different groups ac-
cording to PCI evaluation (0–6; 7–10; > 10).
Five patients (7.8 %) underwent cytoreductive surgery
without HIPEC treatment and therefore have been ex-
cluded from the current study.
Three patients (4.7 %) did a laparoscopic palliative
HIPEC treatment for malignant ascites from breast can-
cer (1 case) and pleuric mesothelioma (2 cases). Of the
other 56 cases (87.5 %), in 44 cases (22 colon cancer, 9
ovaric cancer, 9 gastric cancer, 2 jejunal carcinoma, 1
peritoneal mesothelioma, 1 endometrium), HIPEC treat-
ment was used in a therapeutic setting (PCI > 0).
In 12 (18.7%) patients, HIPEC was performed as adju-
vant treatment for locally advanced gastric cancer.
In two patients (3.1%), an iterative procedure was per-
formed due to peritoneal recurrences from ovarian cancer.
CRS was performed in all the patients, with the intent
to remove all the macroscopic disease. Anterior abdom-
inal peritonectomy, right and left diaphragmatic perito-
nectomy, right and left parietocolic peritonectomy,
greater omentectomy, lesser omentectomy, and pelvic
peritonectomy were performed during the surgical pro-
cedures together with the resection of the abdominal
organs compromised by the tumor.
Small and scattered localizations on visceral surfaces
were resected by local excision or electrocoagulation. All
anastomoses were performed before the beginning of
the intraperitoneal perfusion. Protective ostomies were
performed only in high-risk patients after HIPEC, to
prevent perfusate leak from ostomy tracts through the
abdominal wall.
HIPEC was performed according to the closed-
abdomen technique, at temperature of 42.5 °C, with cis-
platin (25 mg/m2/L) plus doxorubicin (15 mg/L) for
90 min or cisplatin (25 mg/m2/L) plus mitomycin-C
(3.3 mg/m2/L) for 60 min or oxaliplatin (360 mg/L/m2)
for 30 min at the temperature of 43 °C. Perfusate volume
was 4 to 6 L; average flow was 700 mL/min. The Per-
former LRT (RAND, Medolla (MO), Italy) extracorpor-
eal circulation device was used.
The completeness of cytoreduction (CCR) [14] was
classified at the end of the surgical phase, as macro-
scopically complete (CCR-0); nearly complete: residual
disease 2.5 mm or less in any region (CCR-1); or sub-
optimal: residual disease more than 2.5 mm (CCR-2).
All the patients were admitted to the intensive care
unit (ICU) after the surgical procedure for at least 24 h.
Venous blood sampling was taken before surgery and
collected in ethylenediaminetetraacetic acid (EDTA)
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containing tube. The normal range of white blood cells
(WBC) count was from 4000 to 10,800 cells/mm3.
Baseline N/L ratio and N/P ratio were calculated as
neutrophil absolute number count divided by lympho-
cyte or platelets absolute number count.
Median value of N/L ratio (2.12), N/P (0.27) ratio, and
serum albumin (3.8 g/dL) were used to dichotomize pa-
tients in two homogenous groups.
A record of any post-operative complications was made
according to the National Institutes of Health morbidity
and mortality grading system [15].
Adverse events were divided into five categories, as
shown according to Clavien-Dindo classification [16].
Morbidity-mortality-related procedure was considered
within 60 days from the surgical procedure.
OS was calculated according to the Kaplan-Meier
method from the initial date of treatment to the occur-
rence of the event or to the date of the last follow-up
(follow-up in our center is performed for 10 years from
the surgical procedure); differences were determined
using a log-rank test.
Univariate and multivariate analyses were done, and
Cox’s proportional hazard model was used to identify sig-
nificant factors related with prognosis and complications.
A P < 0.05 was regarded as statistically significant.
Research carried out is in compliance with the
Helsinki Declaration.
Graph Pad Prism version 5.0 and SAS statistical soft-
wares were used to generate these analyses.
Results
Between September 2006 and September 2014, 59 con-
secutive combined procedures were performed.
Clinical and pathological features and some surgical
details of the patients are shown in Table 1.
We treated 22 PC originating from colon cancer, 21
PC from gastric cancer, nine PC from ovarian cancer,
two PC from small intestine, one from peritoneal meso-
thelioma, and one from the uterus (Fig. 1).
Excluding three patients with malignant ascites who
underwent palliative laparoscopic HIPEC treatment,
CC0 was achieved in 50 patients (89.3 %), CC1 in 4 pa-
tients (7.1 %), and CC2 in 2 patients (3.6 %) (Fig. 2).
HIPEC was performed in 34 patients with cysplatin
plus mitomycin, in 14 patients with oxaliplatin, and in
four with intraperitoneal infusion of doxorubicin.
In our series, we analyzed a global 5-year OS (Fig. 3)
that was 55 %.
Then, we evaluated OS according to different vari-
ables: PCI, CC score, primitive tumor’s location, pre-
operative serum albumin value, pre-operative N/L ratio,
pre-operative N/P ratio, adjuvant chemotherapy,and
post-surgical complications.
According to PCI, patients were divided into three
subgroups as previously described and OS show a statis-
tically significant difference (P < 0.05) (Fig. 4).
According to primitive tumor site, OS was evaluated
and no statistically significant differences were found,
whereas there was a statistically significant differences
(P < 0.05) between patients who underwent a complete
cytoreduction vs. incomplete (Fig. 5).
OS was also evaluated according to N/L and N/P ratio
with no statistically significant differences (P > 0.05) in
the two groups.
However, OS according to pre-operative serum albu-
min level (Fig. 6) shows a difference in the two groups
with a 5-year OS in the higher group of 70 % vs. a 5-
year OS of 38 % in the lower group (P < 0.05).
We observed minor or no adverse events in 53 cases
(89.8 %), while 3 patients (5.1 %) showed a grade III–IV
complication.
Table 1 Clinical pathological characteristics of our patients'
series
Variables No. of patients Percentage
Median age 59.6 ± 10.58 years old
M/F 26/38
CRS without HIPEC 5 7.8
CRS + HIPEC 59 92.2
Primary tumor:
• Colon 22 34.4
• Gastric 21 32.8
• Ovary 9 14.1
• Other tumor with malignant
ascites
3 4.7
• Other 4 6.2





• 0 50 89.3
• 1 4 7.1
• 2 2 3.6
Neoadjuvant chemotherapy 15 25.4
Adjutant chemotherapy 55 93.2
Adjutant HIPEC 12 20.3
Palliative HIPEC 3 5.1
Intraoperative drugs:
• Cysp. + Myto 34 57.6
• Oxaliplatin 14 23.7
• Doxo 4 6.8
• Other 7 11.9
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There were three post-operative deaths (5.1 %): one due
to a necrotic hemorrhagic pancreatitis in patients with an
anastomotic leakage and two due to acute respiratory dis-
tress syndrome and respiratory failure (Fig. 7).
Post-operative complication also influenced the OS as
shown in Fig. 8; patients in whom a minor complication
(grades I and II) occurred had a 3-year OS of 62 % vs. a
3-year OS of 28 % in patients who underwent a major
complication (P < 0.1).
Performing a univariate analysis using log-rank test,
the following factors were correlated with poorer overall
survival: serum albumin level (P = 0.009); CC score (P
0.002); and complication rate (P 0.015). Serum albumin
level was still significant in the final multivariate model
(HR 5.2; 95 % CI 1.5–18.1; P = 0.009.) as well as CC
score (HR 5.9; 9 5% CI 1.8–18.9; P 0.003) and complica-
tion rate (HR 5.9; 95 % CI 2.0–17.5; P = 0.001).
Discussion
Peritoneal dissemination is a form of cancer progression,
which can frequently affect patients with gastrointestinal
and ovarian cancers having a median survival not ex-
ceeding 6 months.
Fig. 1 Primary tumor distribution in our series (absolute number and percentage)
Fig. 2 Completeness of cytoreduction distribution in our series (CC score)
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For this reason, a handful of centers have pursued ag-
gressive CRS to resect macroscopic disease as much as
possible, combining it with HIPEC to treat any residual
occult disease.
Nowadays, complete CRS plus HIPEC became the new
standard of treatment for peritoneal carcinomatosis giv-
ing promising results with an acceptable morbidity.
However, continuous and meticulous analyses are
needed to enable further improvements to this technique.
As long as the aim of cancer surgery is to cure, then pa-
tient selection remains uncontroversial. Yet, like all other
treatments, CRS and HIPEC must achieve the optimum
risk benefit balance based on data reported in literature.
In this study, we want to report our HIPEC patient re-
sults in terms of overall survival, disease free survival,
and post-operative complications and we correlated
them to various prognostic factors.
Our aim is to better identify patients who could really
benefit of this aggressive treatment with an acceptable
morbidity.
Actually, different scoring systems try to select the
“right patient” to address to this procedure.
Nowadays, there are a number of pre-operative prog-
nostic models published for PC as the peritoneal surface
disease severity score (PSDS) [17], laparoscopic staging
[18], or prognostic score [19].
These methods are based primarily on the extent of
PC in the abdominal cavity.
In contrast, analyses based on blood samples could
provide a simple scoring system.
The colon rectal peritoneal score (COREP) is based
mainly on serum tumor markers and their change be-
tween referral and surgery. The COREP score reflects
the tumor biology and can support radiology to improve
the patient selection process before surgery.
There are, however, other prognostic scores, notably
the PSDS and the prognostic score (PS), appeared be-
cause the pre-operative radiologic evaluation is not able
to exclude patients to surgery only on the basis of PC
extension [20].
Radiologic examinations could individualize metastatic
patients with lung or liver metastases, retroperitoneal
lymphonodes that render the patient surgical ineligible.
These scores are more dependent on the extent of the
PC to predict survival.
Cashin [21] in his study compared in a univariate and
multivariate analyses these three prognostic scores. Al-
though the COREP score was designed to reflect a more
tumor biology perspective rather than tumor burden, it
still correlated to the PCI. This study demonstrates that
the COREP score can identify patients who may quickly
experience systemic recurrence, seeming superior to the
PSDS, and the PS in identifying patients who will not
benefit from CRS and HIPEC.
Recently, Adachi [22] correlated the modified Glasgow
Prognostic Score (mGPS) to the 3-month mortality rate
in patients who undergo surgical intervention with sys-
temic chemotherapy for synchronous PC from CRC.
The mGPS could aid surgeons in choosing the appro-
priate treatment strategy and the best care for patients.
In fact, according to these study results, mGPS was the
only independent risk factor of post-operative mortality.
In our survival analysis, we considered patient-related
parameters (pre-operative serum albumin level; pre-
operative serum neutrophils to lymphocytes and plate-
lets to lymphocytes ratio) and tumor-related factors
(PCI; primary tumor site, CC score).
In addition, we correlated OS to post-surgical compli-
cations occurrence.
Fig. 3 Overall survival (OS) in our series; 5-year OS, 55 %
Fig. 4 Overall survival according to Peritoneal Cancer Index
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Pre-operative serum albumin level is strongly corre-
lated to patient survival.
Both in our univariate and multivariate analysis albu-
min is strongly correlated to patient prognosis. Albumin
has been described as a negative inflammatory marker in
various studies.
Cancer is generally associated with an inflammatory sta-
tus of the patients; as a matter of fact, cancer growth and
its invasion induce local tissue damages, local homeostasis
alteration, and finally a systemic acute-phase response.
The major role of the acute-phase response is to remove
the cause from the body and to restore the initial status;
however, this response persists in case of cancer, and it
contributes to the development of the pathology of dis-
ease, as cancers are “wounds that do not heal” [23].
Alternatively, cancers continue to progress in a non-
self-limiting manner, while inducing their stroma, essential
to growth, by activating the host’s wound healing re-
sponse. Thus, this systemic inflammatory response
(SIR) associated with cancer must be ongoing and per-
sistent. SIR is associated with an induced liver
Fig. 5 Overall survival according to completeness of cytoreduction (P < 0.05)
Fig. 6 Overall survival according to serum albumin level; P < 0.05 Fig. 7 Clavien-Dindo’s complications distribution
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production of acute-phase proteins as protein C-reactive;
IL-6; and IL-1.
These factors, on the other hand, cause a negative
drive to albumin liver synthesis.
Mc Milla et al. [24] also found that a low albumin level
was associated with an elevated phase acute proteins
level, and they concluded that this was likely a secondary
event resulting from ongoing cancer-associated inflam-
mation, not simply from the nutritional decline associ-
ated with food intake disturbance.
Thus, both the increasing of C-reactive Protein (CRP)
and interleukins and albumin decreasing should be cor-
related to the advanced tumor stage and poor prognosis.
In advanced tumors, frequently a high pre-operative
C-reactive protein level is accompanied by high platelet
count associating a poor patient prognosis [25]. The
pre-operative neutrophil-lymphocyte ratio (NLR) also re-
flects patients’ inflammation status, clinical stage, and
patients’ survival in colon cancer, lung cancer, and liver
cancer [26–31].
Increased numbers of neutrophils and/or decreased
numbers of lymphocytes may suppress lymphokine-
activated killer cells, thereby increasing the propensity to
metastasis.
Our patients’ survival is not statistically correlated to
NLR or PLR probably due to the fact that patients
underwent chemotherapy before HIPEC and CRS pro-
cedure altering their immune status and probably also
due to their advanced metastatic disease.
We have previously demonstrated [32] that elevated
pre-operative N/L ratio predicts poor overall survival
following resection in our gastric cancer patients.
Thus this ratio may be utilized as a simple, reliable
prognostic factor for risk stratification but only for pa-
tients at an early stage of disease being T and N stages
more statistically significant in advanced stage of disease.
As demonstrated in other studies [33–35], PCI is obvi-
ously strongly correlated to overall survival. Post-
surgical complications affect long-term outcomes; in fact
patients, showing major morbidity, have a poorer prog-
nosis compared to patients who did not. Previously Bar-
atti et al. [36] analyzed the clinical impact of treatment
related morbidity on survival in patients with colon can-
cer treated with HIPEC and CRS.
At multivariate analysis, major morbidity correlated to
worse overall disease-specific survival independently
from PCI value (11.7 vs. 58.8% of patients who did not
show major post-surgical complications) comparable to
our results.
The mechanisms by which operative complications
impact oncologic outcomes remain controversial. Prob-
ably, we can explain this correlation according to the fol-
lowing hypothesis: (1) there are some biological factors
that predispose patients to both complications and poor
long-term survival, (2) operative morbidity directly af-
fects oncologic post-surgical outcome, and (3) surgeon’s
experience and learning curve affect directly both early
and late post-surgical results.
Regarding the first point, surgery is more technically
demanding in patients with advanced-stage of disease,
resulting in a higher risk of post-operative complications
occurrence.
On the other side, complications may worsen general
conditions and they impede subsequent adjuvant therap-
ies or treatment for recurrence that is need in advanced
disease.
Furthermore, there is evidence that cell-mediated im-
munity and natural killer cell function are suppressed by
surgical stress. Because the immune system has been
suggested to play a role in controlling microscopic re-
sidual disease following surgical resection, complications
might aggravate the negative impact on immunity and
facilitate tumor progression.
We think that prevention of major complication is
fundamental and this can be done by doing a careful pa-
tient selection and improving surgeon learning curve.
In our study, overall grade III and IV morbidity was very
low and mortality was limited to few cases. It could be ex-
plained with the low median PCI, the correct patient se-
lection being certainly the procedure’s “Achilles heel,” and
with the advanced surgical experience of the center.
Conclusions
Our study is limited by the small size of patients and by
the fact that different primary tumor were analyzed giv-
ing heterogeneous results.
Fig. 8 Overall survival according to complications rate P < 0.1
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However, it seems that CRS and HIPEC could be a
valid and feasible option for locally advanced gastro-
intestinal malignancies reporting good survivals. Pre-
operative parameters could be evaluated to rightly
choose patient who could really benefit from HIPEC and
CRS with an acceptable post-surgical morbidity.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GL carried out the study design and the manuscript editing; EM carried out
the manuscript editing, data collection, and statistical analysis; VDA carried
out the manuscript editing and statistical analysis; AR carried out the
manuscript editing and English revision; AD conceived the study and helped
in the manuscript and English revision. All authors read and approved the
final manuscript.
Author details
1Department of General and Emergency Surgery, Santa Maria della
Misericordia Hospital, University of Perugia, Via Dottori, 06132 Perugia, Italy.
2Department of Clinical Oncology, Santa Maria della Misericordia Hospital,
University of Perugia, Perugia, Italy. 3Department of Radiology, Santa Maria
della Misericordia Hospital, University of Perugia, Perugia, Italy.
Received: 23 July 2015 Accepted: 24 March 2016
References
1. Haslinger M et al. A contemporary analysis of morbidity and outcomes in
cytoreduction/hyperthermic intraperitoneal chemoperfusion. Cancer Med.
2013;2(3):334–42.
2. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal
carcinomatosis in nongynecologic malignancy. A prospective study of
prognostic factors. Cancer. 1989;63:364–7.
3. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al.
Peritoneal carcinomatosis from non-gynecologic malignancies: results of the
EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.
4. Verwaal V, Bruin S, Boot H, et al. 8-year follow-up of randomized trial:
cytoreduction and hyperthermic intraperitoneal chemotherapy versus
systemic chemotherapy in patients with peritoneal carcinomatosis of
colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.
5. Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N,
Verwaal VJ, Mohamed F, Mirnezami AH. Cytoreductive surgery in
combination with hyperthermic intraperitoneal chemotherapy improves
survival in patients with colorectal peritoneal metastases compared with
systemic chemotherapy alone. Br J Cancer. 2014;111(8):1500–8.
6. Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse
malignant peritoneal mesothelioma: long-term survival with complete
cytoreductive surgery followed by hyperthermic intraperitoneal
chemotherapy (HIPEC). Eur J Cancer. 2013;49(15):3140–8.
7. Desantis M, Bernard JL, Casanova V, Cegarra-Escolano M, Benizri E, Rahili
AM, Benchimol D, Bereder JM. Morbidity, mortality, and oncological
outcomes of 401 consecutive cytoreductive procedures with hyperthermic
intraperitoneal chemotherapy (HIPEC). Langenbecks Arch Surg.
2014;400:37–48.
8. Stewart IV JH, Shen P, Levine EA. Intraperitoneal hyperthermic
chemotherapy: an evolving paradigm for the treatment of peritoneal
surface malignancies. Expert Rev Anticancer Ther. 2008;8:1809–18.
9. Chua TC, Yan TD, Saxena A, Morris D. Should the treatment of peritoneal
carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy still be regarded as a highly morbid procedure?: a systematic
review of morbidity and mortality. Ann Surg. 2009;249(6):900–7.
10. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M,
Friesenbichler J, Trajanoski S, Stojakovic T, Eberhard K, Leithner A, Pichler M.
The lymphocyte/monocyte ratio predicts poor clinical outcome and
improves the predictive accuracy in patients with soft tissue sarcomas. Int J
Cancer. 2014;135(2):362–70.
11. Yoshioka S, Kubo M, Yanagisawa K, Hata T, Takiuchi D, Hamano R, Minohata
J, Kashiwazaki M, Miki H, Tsujie M, Konishi M, Yano H. Clinical significance of
neutrophil to lymphocyte ratio in colorectal cancer patients receiving
adjuvant chemotherapy combined with polysaccharide-K. Gan To Kagaku
Ryoho. 2013;40(12):2086–8.
12. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, Miyazaki A,
Gunji H, Yamamoto H, Nagata M. High preoperative neutrophil-lymphocyte
ratio predicts poor survival in patients with gastric cancer. Gastric Cancer.
2010;13:170–6.
13. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and
staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;
82:359–74.
14. Sugarbaker PH. Peritonectomy procedurese. Ann Surg. 1995;221:29–42.
15. Kerscher AG, Mallalieu J, Pitroff A, Kerscher F, Esquivel J. Morbidity and
mortality of 109 consecutive cytoreductive procedures with hyperthermic
intraperitoneal chemotherapy (HIPEC) performed at a community hospital.
World J Surg. 2010;34:62–9.
16. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al.
The Clavien-Dindo classification of surgical complications: five-year
experience. Ann Surg. 2009;250:187–96.
17. Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease
severity score on survival in patients with colorectal cancer peritoneal
carcinomatosis undergoing complete cytoreduction and hyperthermic
intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:1330–6.
18. Laterza B, Kusamura S, Baratti D, et al. Role of explorative laparoscopy to
evaluate optimal candidates for cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy (HIPEC) in patients with peritoneal
mesothelioma. In Vivo. 2009;23:187–90.
19. Verwaal VJ, van Tinteren H, van Ruth S, et al. Predicting the survival of
patients with peritoneal carcinomatosis of colorectal origin treated by
aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy.
Br J Surg. 2004;91:739–46.
20. Esquivel J, Garcia SS, Hicken W, Seibel J, Shekitka K, Trout R. Evaluation of a
new staging classification and a Peritoneal Surface Disease Severity Score
(PSDSS) in 229 patients with mucinous appendiceal neoplasms with or
without peritoneal dissemination. J Surg Oncol. 2014;110(6):656–60.
21. Cashin PH, Graf W, Nygren P, Mahteme H. Patient selection for cytoreductive
surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an
observational cohort study. Ann Surg. 2012;256(6):1078–83.
22. Adachi T, Hinoi T, Hattori M, Egi H, Shimomura M, Saito Y, Sawada H,
Miguchi M, Niitsu H, Mukai S, Yano T, Ohdan H. The modified Glasgow
prognostic score for early mortality in patients with synchronous peritoneal
carcinomatosis. Surg Today. 2015;45(11):1396-403.
23. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor
stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.
24. McMillan DC. An inflammation-based prognostic score and its role in the
nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;
67:257–62.
25. Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological
association and therapeutic implication. Chang Gung Med J. 2009;32:471–82.
26. Ietomi K. A study on the role of granulocytes in carcinoma bearing hosts G/L
ratio as a new host indicator. Nippon Gan Chiryo Gakkai Shi. 1990;25:662–71.
27. Satomi A, Murakami S, Ishida K, Mastuki M, Hashimoto T, Sonoda M.
Significance of increased neutrophils in patients with advanced colorectal
cancer. Acta Oncol. 1995;34:69–73.
28. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte
ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181–4.
29. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E.
Neutrophil/lymphocyte ratio and its association with survival after
completeresection in non-small cell lung cancer. J Thorac Cardiovasc Surg.
2009;137:425–8.
30. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, et al.
Elevated preoperative neutrophil-to-lymphocyte ratio predicts survival following
hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34:55–60.
31. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, et al.
Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after
curative resection for hepatocellular carcinoma. World J Surg. 2008;32:1757–62.
32. Graziosi L, Marino E, De Angelis V, Rebonato A, Cavazzoni E, Donini A.
Prognostic value of preoperative neutrophils to lymphocytes ratio in
patients resected for gastric cancer. Am J Surg. 2015;209(2):333–7.
33. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with
surgery and perioperative intraperitoneal chemotherapy: retrospective analysis
of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.
Graziosi et al. World Journal of Surgical Oncology  (2016) 14:97 Page 8 of 9
34. Helm CW, Richard SD, Pan J, et al. Hyperthermic intraperitoneal
chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J
Gynecol Cancer. 2010;20:61–9.
35. Baratti D, Pennacchioli E, Kusamura S, et al. Peritoneal sarcomatosis: is there a
subset of patients who may benefit from cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol. 2010;17:3220–8.
36. Baratti D, Deraco M, Kusamura S, Iusco D. Postoperative complications after
cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
affect long-term outcome of patients with peritoneal metastases from
colorectal cancer: a two-center study of 101 patients. Dis Colon Rectum.
2014;57(7):858–68.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Graziosi et al. World Journal of Surgical Oncology  (2016) 14:97 Page 9 of 9
